We would like to congratulate the winners of this year’s Investigator Award. The chosen winners presented their work at the 5th EAN Congress in Oslo this Summer. The Investigator Award consists of a free registration to the 6th EAN Congress in Paris 2020 and an award certificate.
Please find below the list of winners and their presentation titles:
Elisabeth Synnøve Nilsen Husebye, Bergen, NORWAY
O4103 Language delay in children of mothers with epilepsy is associated with the use of antiepileptic drugs – The Norwegian Mother and Child Cohort Study
Stephanie Hödl, Ghent, BELGIUM
O4102 VNS responders have a significant higher amount of deep sleep – The Adenosine Hypothesis
Michael Leo Strupp, Munich, GERMANY
O2104 Fampridine and acetazolamide for the treatment of episodic ataxia type 2 (EAT2TREAT): a randomised, double – blind, placebo – controlled, three – period crossover trial
Didier Leys, Lille, FRANCE
O1109 Access to mechanical thrombectomy for cerebral ischaemia: a population-based study in the North-of-France.
James F. Howard, Chapel Hill, UNITED STATES OF AMERICA
O1215 Zilucoplan, a subcutaneously self-administered peptide inhibitor of complement component 5 (C5), for the treatment of generalized myasthenia gravis: results of a Phase 2 randomized, double-blind, placebo-controlled trial.
Andrea Cortese, London, UNITED KINGDOM
O3109 A recessive repeat expansion causes CANVAS and is a frequent cause of late-onset sensory ataxia.
Ermelinda De Meo, Milan, ITALY
O1203 In-vivo mapping of thalamic pathological mechanisms in pediatric patients with MS.
Johannes Jernqvist Gaare, Bergen, NORWAY
O1211 Rare variation in biological pathways and their impact on development and progression of Parkinson Disease.
Julie Dreier, Aarhus, DENMARK
O3219 Long-term consequences of recurrent febrile seizures.
Maja Relja, Zagreb, CROATIA
03227 Dystonia in Europe: a survey towards care from a patients perspectives.
Marco Vabanesi, Milan, ITALY
O2115 Acute ischemic stroke due to large vessel occlusion: predicting functional outcome with tissue viability score combining ASPECTS and collateral vessel status.
Nina Grytten, Bergen, NORWAY
O1204 Cancer risk in multiple sclerosis patients, siblings, and healthy controls: a prospective, longitudinal cohort study.
Pawel Kermer, Sanderbusch, GERMANY
O1108 Idarucizumab in Cerebral Ischemia or Intracranial Hemorrhage under Dabigatran therapy in Germany – A Nationwide Case Collection.
Petr Jansky, Praha, CZECH REPUBLIC
EPR2012 Spatial Relation of Blood-Brain Barrier Impairment with the Ischaemic Lesion and Risk of Haemorrhagic Transformation in Ischaemic Stroke Patients.
R.M.A. de Bie, Amsterdam, NETHERLANDS
O3224 Randomized delayed-start trial of levodopa in Parkinson’s disease.
Sally Lee, Summit, NJ, UNITED STATES OF AMERICA
O1206 Cause and Age of Mortality in Patients Diagnosed with Multiple Sclerosis.
Sonu Bhaskar, Sydney, AUSTRALIA – 2-time winner
O1106 Cryptogenic stroke is linked to cardioembolic aetiology: A histopathological study of thrombus retrieved after endovascular thrombectomy.
and
EPR1111 Erythrocyte-rich clots are associated with cardioembolic aetiology, reduced number of manoeuvres, and improved clinical outcome in acute ischemic stroke patients.
Stefanie Smolders, Antwerp, BELGIUM
O1233 Compound heterozygous and homozygous mutations reducing VPS13C protein expression are associated with Lewy body disease and Parkinson disease.
Thomas Rambaud, Paris, FRANCE
O3202 Patients with high post-endovascular treatment plasma levels of neutrophil activation markers are at higher risk of poor functional outcome, HT, and mortality.
